Kuros Biosciences AG

Kuros Biosciences AG is a Switzerland-based biotechnology company specializing in the discovery, development, and commercialization of innovative biologic technologies for bone healing and regeneration. Headquartered in Schlieren, with operations in the Netherlands and the USA, it focuses on advanced medical devices like the MagnetOs family of synthetic bone grafts, including Granules, Putty, Flex Matrix, and Easypack Putty, which have received FDA clearances for standalone, interbody, extremities, and pelvis applications. The company transitioned from a legacy biotechnology portfolio to dominate in medical devices, with sales surging from 8.34 million CHF in 2021 to 75.56 million CHF in 2024, primarily driven by the US market at 72.84 million CHF. Employing 158 people, Kuros Biosciences AG advances orthopedics and spinal applications through rigorous clinical evidence, such as Level 1 studies published in Spine journal, and strategic partnerships like with Medtronic's spinal division. Led by CEO Christopher Fair since 2023, it plays a key role in the biotechnology and medical research sector by addressing unmet needs in bone grafting with high-quality, evidence-based solutions.